Clarification on Abrysvo® and Beyfortus™ Availability

Recent media coverage has caused some confusion regarding the inclusion of the Abrysvo® RSV vaccine for pregnant women in the National Immunisation Program (NIP). To clarify: 

1️⃣ Misinterpretation: Abrysvo® is currently available through the NIP.

Correction: While Abrysvo® will be added to the NIP, it will not be available through this program until early 2025. At present, the vaccine is only accessible on the private market. If purchased, it is not eligible for reimbursement under the NIP.

2️⃣ Misinterpretation: Beyfortus™ (nirsevimab), a monoclonal antibody for newborns, will be part of the NIP in 2025.

Correction: Beyfortus™ will not be funded through the NIP. Instead, access to this medication for newborns and young children will be provided by individual States and Territories. 

We encourage healthcare professionals to ensure patients are aware of these details, as some may mistakenly believe these vaccinations are already available through the NIP.